The DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.
Psoriasis: Which therapy for which patient
Abstract
Psoriasis is a systemic inflammatory disease associated with increased risk of comorbidities, such as psoriatic arthritis, Crohn's disease, malignancy, obesity, and cardiovascular diseases. These factors have a significant impact on the decision to use one therapy over another. The past decade has seen a paradigm shift in our understanding of the pathogenesis of psoriasis that has led to identification of new therapeutic targets. Several new drugs have gained approval by the US Food and Drug Administration, expanding the psoriasis armamentarium, but still a large number of patients continue to be untreated or undertreated. Treatment regimens for psoriasis patients should be tailored to meet the specific needs based on disease severity, the impact on quality of life, the response to previous therapies, and the presence of comorbidities. The first article in this continuing medical education series focuses on specific comorbidities and provides insights to choose appropriate systemic treatment in patients with moderate to severe psoriasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
Abraham, C., & Cho, J. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804647 · Cited by 2,712
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
Risk of myocardial infarction in patients with psoriasis
Gelfand, J. M., Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., & Troxel, A. B. (2006) · JAMA · doi:10.1001/jama.296.14.1735 · Cited by 1,899
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
Feagan, B. G., Sandborn, W. J., Gasink, C., Jacobstein, D., Lang, Y., Friedman, J. R., Blank, M. A., Johanns, J., Gao, L.-L., Miao, Y., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602773 · Cited by 1,845
Hanauer, S. B., Sandborn, W. J., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D., Panaccione, R., Wolf, D., & Pollack, P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.030 · Cited by 1,715
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Gottlieb, A., Feldman, S. R., Van Voorhees, A. S., Leonardi, C. L., Gordon, K. B., Lebwohl, M., Koo, J. Y. M., Elmets, C. A., Korman, N. J., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.039 · Cited by 1,222
Self-citationPsoriasis and comorbid diseases
Takeshita, J., Grewal, S., Langan, S. M., Mehta, N. N., Ogdie, A., Van Voorhees, A. S., & Gelfand, J. M. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.07.064 · Cited by 1,145
The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
Di Cesare, A., Di Meglio, P., & Nestle, F. O. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.59 · Cited by 1,129
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Papp, K. A., Leonardi, C., Menter, A., Ortonne, J.-P., Krueger, J. G., Kricorian, G., Aras, G., Li, J., Russell, C. B., Thompson, E. H. Z., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109017 · Cited by 941
Sandborn, W. J., Feagan, B. G., Marano, C., Zhang, H., Strauss, R., Johanns, J., Adedokun, O. J., Guzzo, C., Colombel, J.-F., Reinisch, W., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.05.048 · Cited by 940
Mease, P. J., Gladman, D. D., Ritchlin, C. T., Ruderman, E. M., Steinfeld, S. D., Choy, E. H. S., Sharp, J. T., Ory, P. A., Perdok, R. J., & Weinberg, M. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21306 · Cited by 909
McInnes, I. B., Mease, P. J., Kirkham, B., Kavanaugh, A., Ritchlin, C. T., Rahman, P., van der Heijde, D., Landewé, R., Conaghan, P. G., Gottlieb, A. B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61134-5 · Cited by 858
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
Gordon, K. B., Blauvelt, A., Papp, K. A., Langley, R. G., Luger, T., Ohtsuki, M., Reich, K., Amato, D., Ball, S. G., Braun, D. K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1512711 · Cited by 848
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., Papp, K., Spelman, L., Toth, D., Kerdel, F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503824 · Cited by 828
Self-citationSecukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Mease, P. J., McInnes, I. B., Kirkham, B., Kavanaugh, A., Rahman, P., van der Heijde, D., Landewé, R., Nash, P., Pricop, L., Yuan, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412679 · Cited by 746
Saurat, J. ‐., Stingl, G., Dubertret, L., Papp, K. A., Langley, R. G. B., Ortonne, J. ‐., Unnebrink, K., Kaul, M., Camez, A., & for the CHAMPION Study Investigators (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08315.x · Cited by 728
Ritchlin, C., Rahman, P., Kavanaugh, A., McInnes, I. B., Puig, L., Li, S., Wang, Y., Shen, Y.-K., Doyle, M. K., Mendelsohn, A. M., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204655 · Cited by 662
Kavanaugh, A., McInnes, I., Mease, P., Krueger, G. G., Gladman, D., Gomez‐Reino, J., Papp, K., Zrubek, J., Mudivarthy, S., Mack, M., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24403 · Cited by 602
Mease, P. J., van der Heijde, D., Ritchlin, C. T., Okada, M., Cuchacovich, R. S., Shuler, C. L., Lin, C.-Y., Braun, D. K., Lee, C. H., & Gladman, D. D. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209709 · Cited by 580
Wolfe, F., & Michaud, K. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22864 · Cited by 534
Lebwohl, M. G., Bachelez, H., Barker, J., Girolomoni, G., Kavanaugh, A., Langley, R. G., Paul, C. F., Puig, L., Reich, K., & van de Kerkhof, P. C. M. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.12.018 · Cited by 515
Self-citationArmstrong, A. W., Harskamp, C. T., & Armstrong, E. J. (2012) · Nutrition & Diabetes · doi:10.1038/nutd.2012.26 · Cited by 514
Paul, C., Cather, J., Gooderham, M., Poulin, Y., Mrowietz, U., Ferrandiz, C., Crowley, J., Hu, C., Stevens, R. M., Shah, K., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14164 · Cited by 484
Segal, B. M., Constantinescu, C. S., Raychaudhuri, A., Kim, L., Fidelus-Gort, R., & Kasper, L. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70173-x · Cited by 479
Armstrong, E. J., Harskamp, C. T., & Armstrong, A. W. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000062 · Cited by 470
Papp, K. A., Reich, K., Paul, C., Blauvelt, A., Baran, W., Bolduc, C., Toth, D., Langley, R. G., Cather, J., Gottlieb, A. B., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14493 · Cited by 470
Drug-induced systemic lupus erythematosus associated with etanercept therapy
Shakoor, N., Michalska, M., Harris, C. A., & Block, J. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07714-0 · Cited by 458
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
Kwon, H. J., Cot, T. R., Cuffe, M. S., Kramer, J. M., & Braun, M. M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-10-200305200-00008 · Cited by 455
Feagan, B. G., Sandborn, W. J., D'Haens, G., Panés, J., Kaser, A., Ferrante, M., Louis, E., Franchimont, D., Dewit, O., Seidler, U., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30570-6 · Cited by 451
Papp, K. A., Griffiths, C. E. M., Gordon, K., Lebwohl, M., Szapary, P. O., Wasfi, Y., Chan, D., Hsu, M.-C., Ho, V., Ghislain, P. D., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12214 · Cited by 415
Self-citationNash, P., Kirkham, B., Okada, M., Rahman, P., Combe, B., Burmester, G.-R., Adams, D. H., Kerr, L., Lee, C., Shuler, C. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31429-0 · Cited by 405
Mariette, X., Matucci-Cerinic, M., Pavelka, K., Taylor, P., van Vollenhoven, R., Heatley, R., Walsh, C., Lawson, R., Reynolds, A., & Emery, P. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.149419 · Cited by 404
De Bandt, M., Sibilia, J., Le Loët, X., Prouzeau, S., Fautrel, B., Marcelli, C., Boucquillard, E., Siame, J. L., Mariette, X., & Inflammation, T. C. R. E. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1715 · Cited by 401
Nast, A., Gisondi, P., Ormerod, A. D., Saiag, P., Smith, C., Spuls, P. I., Arenberger, P., Bachelez, H., Barker, J., Dauden, E., et al. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13354 · Cited by 399
Bavinck, J. N., Tieben, L. M., Van der Woude, F. J., Tegzess, A. M., Hermans, J., ter Schegget, J., & Vermeer, B. J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.1933 · Cited by 397
Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
Mease, P. J., Genovese, M. C., Greenwald, M. W., Ritchlin, C. T., Beaulieu, A. D., Deodhar, A., Newmark, R., Feng, J., Erondu, N., & Nirula, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315231 · Cited by 395
Schiff, M. H., Burmester, G. R., Kent, J. D., Pangan, A. L., Kupper, H., Fitzpatrick, S. B., & Donovan, C. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.043166 · Cited by 390
Risk of Malignancies in Psoriasis Patients Treated with Cyclosporine: a 5 y Cohort Study
Paul, C. F., HO, V. C., McGeown, C., et al. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12040.x · Cited by 388
Bozkurt, B., Torre-Amione, G., Warren, M. S., Whitmore, J., Soran, O. Z., Feldman, A. M., & Mann, D. L. (2001) · Circulation · doi:10.1161/01.cir.103.8.1044 · Cited by 388
PRODANOWICH, S., MA, F., TAYLOR, J., PEZON, C., FASIHI, T., & KIRSNER, R. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.06.017 · Cited by 384
Papp, K. A., Langley, R. G., Sigurgeirsson, B., Abe, M., Baker, D. R., Konno, P., Haemmerle, S., Thurston, H. J., Papavassilis, C., & Richards, H. B. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12110 · Cited by 360
McInnes, I. B., Sieper, J., Braun, J., Emery, P., van der Heijde, D., Isaacs, J. D., Dahmen, G., Wollenhaupt, J., Schulze-Koops, H., Kogan, J., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202646 · Cited by 343
Differential regulation of interleukin 17 and interferon production in inflammatory bowel disease
Rovedatti, L., Kudo, T., Biancheri, P., Sarra, M., Knowles, C. H., Rampton, D. S., Corazza, G. R., Monteleone, G., Di Sabatino, A., & MacDonald, T. T. (2009) · Gut · doi:10.1136/gut.2009.182170 · Cited by 338
Co-morbidity and Age-related Prevalence of Psoriasis: Analysis of Health Insurance Data in Germany
Augustin, M., Reich, K., Glaeske, G., Schaefer, I., & Radtke, M. (2010) · Acta Dermato Venereologica · doi:10.2340/00015555-0770 · Cited by 337
Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan
Tsai, T.-F., Wang, T.-S., Hung, S.-T., Tsai, P. I.-C., Schenkel, B., Zhang, M., & Tang, C.-H. (2011) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2011.03.002 · Cited by 323
Autoimmune diseases induced by biological agents
Ramos-Casals, M., Roberto-Perez-Alvarez, Diaz-Lagares, C., Cuadrado, M.-J., & Khamashta, M. A. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.10.003 · Cited by 323
A randomized placebo-controlled trial of methotrexate in psoriatic arthritis
Kingsley, G. H., Kowalczyk, A., Taylor, H., Ibrahim, F., Packham, J. C., McHugh, N. J., Mulherin, D. M., Kitas, G. D., Chakravarty, K., Tom, B. D. M., et al. (2012) · Rheumatology · doi:10.1093/rheumatology/kes001 · Cited by 322
Papp, K. A., Gottlieb, A. B., Naldi, L., Pariser, D., Ho, V., Goyal, K., Fakharzadeh, S., Chevrier, M., Calabro, S., Langholff, W., et al. (2015) · PubMed · Cited by 312
Minozzi, S., Bonovas, S., Lytras, T., Pecoraro, V., González-Lorenzo, M., Bastiampillai, A. J., Gabrielli, E. M., Lonati, A. C., Moja, L., Cinquini, M., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1240783 · Cited by 308
Goodkin, D. E., Rudick, R. A., Medendorp, S. V., Daughtry, M. M., Schwetz, K. M., Fischer, J., & van Dyke, C. (1995) · Annals of Neurology · doi:10.1002/ana.410370108 · Cited by 304
van de Kerkhof, P. C. M., Griffiths, C. E. M., Reich, K., Leonardi, C. L., Blauvelt, A., Tsai, T.-F., Gong, Y., Huang, J., Papavassilis, C., & Fox, T. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.03.024 · Cited by 302
Askling, J., Fahrbach, K., Nordstrom, B., Ross, S., Schmid, C. H., & Symmons, D. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2046 · Cited by 301
Villani, A. P., Rouzaud, M., Sevrain, M., Barnetche, T., Paul, C., Richard, M.-A., Beylot-Barry, M., Misery, L., Joly, P., Le Maitre, M., et al. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.05.001 · Cited by 300
Mease, P., Genovese, M. C., Gladstein, G., Kivitz, A. J., Ritchlin, C., Tak, P. P., Wollenhaupt, J., Bahary, O., Becker, J., Kelly, S., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30176 · Cited by 300
Ryan, C., Leonardi, C. L., Krueger, J. G., Kimball, A. B., Strober, B. E., Gordon, K. B., Langley, R. G., de Lemos, J. A., Daoud, Y., Blankenship, D., et al. (2011) · JAMA · doi:10.1001/jama.2011.1211 · Cited by 289
Edwards, C. J., Blanco, F. J., Crowley, J., Birbara, C. A., Jaworski, J., Aelion, J., Stevens, R. M., Vessey, A., Zhan, X., & Bird, P. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207963 · Cited by 287
Methotrexate for induction of remission in refractory Crohn's disease
McDonald, J. W., Wang, Y., Tsoulis, D. J., MacDonald, J. K., & Feagan, B. G. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003459.pub4 · Cited by 270
The inflammatory response in mild and in severe psoriasis
Rocha-Pereira, P., Santos-Silva, A., Rebelo, I., Figueiredo, A., Quintanilha, A., & Teixeira, F. (2004) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2004.05984.x · Cited by 258
Ash, Z., Gaujoux-Viala, C., Gossec, L., Hensor, E. M., FitzGerald, O., Winthrop, K., van der Heijde, D., Emery, P., Smolen, J. S., & Marzo-Ortega, H. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.150995 · Cited by 258
Low-Dose Cyclosporine for the Treatment of Crohn's Disease
Feagan, B. G., McDonald, J., Rochon, J., Laupacis, A., Fedorak, R. N., Kinnear, D., Saibil, F., Groll, A., Archambault, A., Gillies, R., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406303302602 · Cited by 254
Treatments for psoriasis and the risk of malignancy
Patel, R. V., Clark, L. N., Lebwohl, M., & Weinberg, J. M. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.12.031 · Cited by 235
Self-citationThe association of psoriasis with autoimmune diseases
Wu, J. J., Nguyen, T. U., Poon, K.-Y. T., & Herrinton, L. J. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.04.039 · Cited by 226
TNFα in myocardial ischemia/reperfusion, remodeling and heart failure
Kleinbongard, P., Schulz, R., & Heusch, G. (2011) · Heart Failure Reviews · doi:10.1007/s10741-010-9180-8 · Cited by 226
Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis
Gisondi, P., Targher, G., Zoppini, G., & Girolomoni, G. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.020 · Cited by 225
Havrdová, E., Belova, A., Goloborodko, A., Tisserant, A., Wright, A., Wallstroem, E., Garren, H., Maguire, R. P., & Johns, D. R. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8128-x · Cited by 224
Problems encountered during anti-tumour necrosis factor therapy
Desai, S. B., & Furst, D. E. (2006) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2006.06.002 · Cited by 221
Raaschou, P., Simard, J. F., Holmqvist, M., Askling, J., & for the ARTIS Study Group (2013) · BMJ · doi:10.1136/bmj.f1939 · Cited by 213
Cutolo, M., Myerson, G. E., Fleischmann, R. M., Lioté, F., Díaz-González, F., Van den Bosch, F., Marzo-Ortega, H., Feist, E., Shah, K., Hu, C., et al. (2016) · The Journal of Rheumatology · doi:10.3899/jrheum.151376 · Cited by 211
Williams, E. L., Gadola, S., & Edwards, C. J. (2009) · Rheumatology · doi:10.1093/rheumatology/kep080 · Cited by 207
Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women
Li, W.-Q., Han, J.-L., Chan, A. T., & Qureshi, A. A. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202143 · Cited by 196
Psoriasis associated with ulcerative colitis and Crohn's disease
Cohen, A., Dreiher, J., & Birkenfeld, S. (2009) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2008.03031.x · Cited by 195
Edwards, L. J., & Constantinescu, C. S. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1087oa · Cited by 193
Rosenberg, P., Urwitz, H., Johannesson, A., Ros, A.-M., Lindholm, J., Kinnman, N., & Hultcrantz, R. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.01.024 · Cited by 185
Carneiro, J. R. I., & Sato, E. I. (1999) · PubMed · Cited by 178
Ahlehoff, O., Skov, L., Gislason, G., Lindhardsen, J., Kristensen, S. L., Iversen, L., Lasthein, S., Gniadecki, R., Dam, T. N., Torp‐Pedersen, C., et al. (2013) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02593.x · Cited by 177
Medical comorbidity associated with psoriasis in adults: a population-based study
Yang, Y.-W., Keller, J. J., & Lin, H.-C. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10494.x · Cited by 176
McKENNA, & MURPHY (1999) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1999.02765.x · Cited by 174
Zhu, Y., Hu, C., Lu, M., Liao, S., Marini, J. C., Yohrling, J., Yeilding, N., Davis, H. M., & Zhou, H. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008329556 · Cited by 173
Fortin, P. R., Abrahamowicz, M., Ferland, D., Lacaille, D., Smith, C. D., Zummer, M., & Canadian Network For Improved Outcomes in Systemic Lupus Erythematosus (2008) · Arthritis Care & Research · doi:10.1002/art.24068 · Cited by 165
Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis
Menter, A., Gordon, K. B., Leonardi, C. L., Gu, Y., & Goldblum, O. M. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.09.040 · Cited by 164
Autoimmune disease in families with multiple sclerosis: a population-based study
Ramagopalan, S. V., Dyment, D. A., Valdar, W., Herrera, B. M., Criscuoli, M., Yee, I. M. L., Sadovnick, A. D., & Ebers, G. C. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70132-1 · Cited by 163
Fiorentino, D., Ho, V., Lebwohl, M. G., Leite, L., Hopkins, L., Galindo, C., Goyal, K., Langholff, W., Fakharzadeh, S., Srivastava, B., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.07.013 · Cited by 159
Self-citationEuropean trial of cyclosporine in chronic active Crohn's disease: A 12-month study
Stange, E. F., Modigliani, R., Peña, A. S., Wood, A. J., Feutren, G., & Smith, P. R. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90384-4 · Cited by 152
Effect of cyclosporine on blood pressure
Robert, N., Wong, G. W., & Wright, J. M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007893.pub2 · Cited by 143
Gordon, K. B., Papp, K. A., Langley, R. G. B., HO, V. C., Kimball, A. B., Guzzo, C. A., Yeilding, N. M., Szapary, P. O., Fakharzadeh, S. S., Li, S., et al. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.06.041 · Cited by 142
Smith, K. J., & Skelton, H. G. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.117725 · Cited by 137
Langer-Gould, A. M., Albers, K., Eeden, S. K. V. D., & Nelson, L. M. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510369146 · Cited by 135
The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study
Abuabara, K., Lee, H., & Kimball, A. B. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10525.x · Cited by 134
Rezzani, R. (2006) · PubMed · doi:10.14670/hh-21.301 · Cited by 133
Risk of Multiple Sclerosis in Patients with Psoriasis: A Danish Nationwide Cohort Study
Egeberg, A., Mallbris, L., Gislason, G., Skov, L., & Hansen, P. R. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.350 · Cited by 133
Rovedatti, L., Sabatino, A. D., Kudo, T., Biancheri, P., Sarra, M., Monteleone, G., Corazza, G. R., & MacDonald, T. T. (2009) · Digestive and Liver Disease · doi:10.1016/s1590-8658(09)60019-0 · Cited by 131
Paty, D. W., & Li, D. K. (2001) · PubMed · Cited by 130
Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients
Kural, B. V., Örem, A., Çimşit, G., Uydu, H. A., Yandı, Y. E., & Alver, A. (2003) · Clinica Chimica Acta · doi:10.1016/s0009-8981(03)00082-2 · Cited by 128
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis
Pathan, E., Abraham, S., Rossen, E. V., Withrington, R. H., Keat, A., Charles, P. J., Paterson, E., Chowdhury, M., McClinton, C., & Taylor, P. C. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201915 · Cited by 128
Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: An ongoing story
Caminero, A. B., Comabella, M., & Montalbán, X. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.03.004 · Cited by 126
Pragmatic approaches to therapy for systemic lupus erythematosus
Xiong, W., & Lahita, R. G. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.157 · Cited by 117
Targeting Myocardial Remodelling to Develop Novel Therapies for Heart Failure
Tarone, G., Balligand, J., Bauersachs, J. K., Clerk, A., Windt, L. J. D., Heymans, S. R. B., Hilfiker‐Kleiner, D., Hirsch, E., Iaccarino, G., Knöll, R., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.62 · Cited by 114
Efficacy of etanercept in an integrated multistudy database of patients with psoriasis
Gordon, K. B., Korman, N. J., Frankel, E., et al. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.11.1088 · Cited by 112
Wetter, D. A., & Davis, M. D. P. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.11.979 · Cited by 108
de Sévaux, R. G. L., Smit, J. V., de Jong, E. M. G. J., van de Kerkhof, P. C. M., & Hoitsma, A. J. (2003) · Journal of the American Academy of Dermatology · doi:10.1067/s0190-9622(03)01831-0 · Cited by 104
The Relationship of Obesity With the Severity of Psoriasis: A Systematic Review
Fleming, P., Kraft, J. N., Gulliver, W. P. F., & Lynde, C. W. (2015) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475415586332 · Cited by 100
Reich, K., Leonardi, C. L., Langley, R. G. B., Warren, R. B., Bachelez, H., Romiti, R., Ohtsuki, M., Xu, W., Acharya, N. V., Solotkin, K. C., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.10.027 · Cited by 99
Frequency of Malignant Neoplasms in 248 Long-Term Methotrexate-Treated Psoriatics
Nyfors, A., & Jensen, H. (2009) · Dermatologica · doi:10.1159/000249793 · Cited by 97
Psoriasis and Risk of Heart Failure: A Nationwide Cohort Study
Khalid, U., Ahlehoff, O., Gislason, G., Kristensen, S. L., Skov, L., Torp-Pedersen, C. T., & Hansen, P. R. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.113 · Cited by 96
Edson‐Heredia, E., Zhu, B., Lefevre, C., Wang, M., Barrett, A., Bushe, C., Cox, A., Wu, J. J., & Maeda‐Chubachi, T. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12742 · Cited by 95
Bissonnette, R., Harel, F., Krueger, J. G., Guertin, M., Chabot-Blanchet, M., Gonzalez, J., Maari, C., Delorme, I., Lynde, C. W., & Tardif, J. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.02.977 · Cited by 93
Neurological adverse events associated with anti-tumor necrosis factor alpha treatment
Tristano, A. G. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5591-7 · Cited by 87
Kestens, C., van Oijen, M. G. H., Mulder, C. L. J., Bodegraven, A. A. V., Dijkstra, G. D. H., de Jong, D., Ponsioen, C. Y., van Tuyl, B. A. C., Siersema, P. D., Fidder, H. H., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.01.012 · Cited by 87
CYCLOSPORIN A IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF AN OPEN CLINICAL STUDY
Manger, K., Kalden, J. R., & Manger, B. (1996) · Rheumatology · doi:10.1093/rheumatology/35.7.669 · Cited by 79
Bissonnette, R., Tardif, J., Harel, F., Pressacco, J., Bolduc, C., & Guertin, M. (2012) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.112.975730 · Cited by 76
Epstein-Barr Virus-Associated Lymphoproliferative Disease During Methotrexate Therapy for Psoriasis
Paul, C. F. (1997) · Archives of Dermatology · doi:10.1001/archderm.1997.03890430083011 · Cited by 74
Non‐alcoholic fatty liver disease fibrosis score in patients with psoriasis
Gisondi, P., Barba, E., & Girolomoni, G. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13456 · Cited by 74
Bonovas, S., Minozzi, S., Lytras, T., González‐Lorenzo, M., Pecoraro, V. L., Colombo, S., Polloni, I., Moja, L., Cinquini, M., Marino, V., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1238458 · Cited by 73
The use of methotrexate in steroid‐resistant systemic lupus erythematosus
Rothenberg, R. J., Graziano, F. M., Grandone, J. T., Goldberg, J. W., BJARNASON, D. F., & Finesilver, A. G. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310505 · Cited by 71
Management of Moderate to Severe Psoriasis in Patients with Metabolic Comorbidities
Gisondi, P., Galvan, A., Idolazzi, L., & Girolomoni, G. (2015) · Frontiers in Medicine · doi:10.3389/fmed.2015.00001 · Cited by 69
Gansauge, S., Breitbart, A., Rinaldi, N., & Schwarz-Eywill, M. (1997) · Annals of the Rheumatic Diseases · doi:10.1136/ard.56.6.382 · Cited by 68
Sandborn, W. J., Schreiber, S., Hanauer, S. B., Colombel, J., Bloomfield, R., & Lichtenstein, G. R. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.03.024 · Cited by 65
Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy
Iannone, F., Lopalco, G., Rigante, D., Orlando, I., Cantarini, L., & Lapadula, G. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.01.010 · Cited by 64
Souza, A. D., Strober, B. E., Merola, J. F., Oliver, S. J., & Franks, A. G. (2012) · PubMed · Cited by 63
Lee, S. Y., Jamal, M. M., Nguyen, E. T., Bechtold, M. L., & Nguyen, D. L. (2015) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000496 · Cited by 62
Apremilast in psoriasis – a prospective real‐world study
Vujic, I., Herman, R., Sanlorenzo, M., Posch, C., Itzinger-Monshi, B., Rappersberger, K., & Richter, L. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14598 · Cited by 60
The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure
Gong, K., Zhang, Z., Sun, X., Zhang, X., Li, A., Yan, J., Luo, Q., Gao, Y., & Feng, Y. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.02.040 · Cited by 56
Multiple Sclerosis Onset during Etanercept Treatment
Gómez-Gallego, M., Meca-Lallana, J. E., & Fernández-Barreiro, A. (2007) · European Neurology · doi:10.1159/000109576 · Cited by 48
Reich, K., Puig, L., Mallbris, L., Zhang, L., Osuntokun, O. O., & Leonardi, C. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14252 · Cited by 46
Nannini, C., Cantini, F., Niccoli, L., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24506 · Cited by 42
Methotrexate for induction of remission in refractory Crohn's disease
McDonald, J. W., Tsoulis, D. J., MacDonald, J. K., et al. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003459.pub3 · Cited by 41
Drug-induced lupus erythematosus in a patient treated with adalumimab
Spillane, A. P., Xia, Y., & Sniezek, P. J. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.01.040 · Cited by 37
Zhao, G. J., Li, D. K. B., Wolinsky, J. S., et al. (1997) · Journal of Neuroimaging · doi:10.1111/jon1997711 · Cited by 37
Prussick, R. B., Unnebrink, K., & Valdecantos, W. C. (2015) · PubMed · Cited by 36
Wu, J. J., & Poon, K. T. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.04.035 · Cited by 28
Etanercept and squamous cell carcinoma
Burge, D. J. (2003) · Journal of the American Academy of Dermatology · doi:10.1067/s0190-9622(03)00811-9 · Cited by 26
Ashtari, F., & Savoj, M.-R. (2011) · PubMed · Cited by 26
Gulliver, W. P. F., Young, H. M., Bachelez, H., Randell, S., Gulliver, S. R., & Al-Mutairi, N. (2016) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475416658004 · Cited by 18
Immunosuppression on the Horizon
Eisen, H. J. (2007) · Heart Failure Clinics · doi:10.1016/j.hfc.2007.03.002 · Cited by 16
Brewer, J. D., Hoverson, A. R., & Roenigk, R. K. (2011) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2011.05024.x · Cited by 13
Komuro (2001) · doi:10.1002/1529-0131(200112)44:12
Cited by
Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E., & Barker, J. N. W. N. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32549-6 · Cited by 2,383
Signaling pathways and targeted therapies for psoriasis
Guo, J., Zhang, H., Lin, W., Lu, L., Su, J., & Chen, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01655-6 · Cited by 427
Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition
Scher, J. U., Ogdie, A., Merola, J. F., & Ritchlin, C. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0175-0 · Cited by 394
Qu, F., Geng, R., Liu, Y., & Zhu, J. (2022) · Theranostics · doi:10.7150/thno.69999 · Cited by 321
Challenges and Future Trends in the Treatment of Psoriasis
Lee, H.-J., & Kim, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713313 · Cited by 315
Metadata
- Authors
- Kaushik, S. B., & Lebwohl, M. G.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 80
- Issue
- 1
- Pages
- 27-40
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W2831987875
- Cited by
- 368
- References
- 142
- FWCI
- 14.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.